BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16164494)

  • 1. Bleeding complications in patients on celecoxib and warfarin.
    Chung L; Chakravarty EF; Kearns P; Wang C; Bush TM
    J Clin Pharm Ther; 2005 Oct; 30(5):471-7. PubMed ID: 16164494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
    Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin.
    Cheetham TC; Levy G; Niu F; Bixler F
    Ann Pharmacother; 2009 Nov; 43(11):1765-73. PubMed ID: 19809010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
    Battistella M; Mamdami MM; Juurlink DN; Rabeneck L; Laupacis A
    Arch Intern Med; 2005 Jan; 165(2):189-92. PubMed ID: 15668365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients.
    Hauta-Aho M; Tirkkonen T; Vahlberg T; Laine K
    Ann Med; 2009; 41(8):619-28. PubMed ID: 19711211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK; Castellsague J; Walker AM
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
    Khurram Z; Chou E; Minutello R; Bergman G; Parikh M; Naidu S; Wong SC; Hong MK
    J Invasive Cardiol; 2006 Apr; 18(4):162-4. PubMed ID: 16729401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
    Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
    Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants.
    Lanas A; García-Rodríguez LA; Arroyo MT; Bujanda L; Gomollón F; Forné M; Aleman S; Nicolas D; Feu F; González-Pérez A; Borda A; Castro M; Poveda MJ; Arenas J;
    Am J Gastroenterol; 2007 Mar; 102(3):507-15. PubMed ID: 17338735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial.
    Dentali F; Douketis JD; Woods K; Thabane L; Foster G; Holbrook A; Crowther M
    Ann Pharmacother; 2006; 40(7-8):1241-7. PubMed ID: 16804099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation.
    Boulanger L; Hauch O; Friedman M; Foster T; Dixon D; Wygant G; Menzin J
    Ann Pharmacother; 2006 Jun; 40(6):1024-9. PubMed ID: 16735649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancies in identification of major bleeding events in patients taking warfarin.
    Seto AC; Kenyon K; Wittkowsky AK
    Pharmacotherapy; 2008 Sep; 28(9):1098-103. PubMed ID: 18752380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
    Rahme E; Barkun AN; Toubouti Y; Scalera A; Rochon S; Lelorier J
    Arthritis Rheum; 2007 Jun; 57(5):748-55. PubMed ID: 17530673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding.
    Delaney JA; Opatrny L; Brophy JM; Suissa S
    CMAJ; 2007 Aug; 177(4):347-51. PubMed ID: 17698822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.